AVTI: AI 评分 45/100 — AI 分析 (4月 2026)

Avitar, Inc. operates as a holding company, focusing on the design, development, manufacture, and marketing of diagnostic test products and proprietary hydrophilic polyurethane foam disposables. Their product offerings include onsite drug detection systems and medical-grade foam disposables, targeting medical, diagnostic, dental, and consumer applications.

Key Facts: AI Score: 45/100 Sector: Healthcare

公司概况

概要：

Avitar, Inc. is a holding company specializing in diagnostic testing and medical disposables, offering onsite drug detection systems and hydrophilic polyurethane foam products. Targeting medical, diagnostic, dental, and consumer sectors, the company utilizes direct sales and strategic partnerships for distribution within the United States.

AVTI是做什么的？

Founded in 1986 and based in Canton, Massachusetts, Avitar, Inc. functions as a holding company with a focus on the healthcare and diagnostics industries. The company, through its subsidiaries, designs, develops, manufactures, and markets a range of diagnostic test products and proprietary hydrophilic polyurethane foam disposables. These products cater to medical, diagnostics, dental, and consumer applications within the United States. Avitar's offerings include ORALscreen 4 and ORALscreen DRUGOMETER, oral fluid-based onsite assay systems designed for the detection of drugs of abuse, such as opiates, cocaine, marijuana, and methamphetamines. Additionally, the company provides medical-grade hydrophilic polyurethane foam disposables, including wound dressings like Hydrasorb, and custom foam products such as sinus dressings and devices used by astronauts for ear pressure relief. Avitar also develops specialty wound dressings for the cardiac catheter lab market and the Illizarov Dressing for orthopedic procedures. The company markets its products through a direct sales force, strategic partners, and a network of distributors, targeting employers, diagnostic test distributors, medical supply companies, governmental agencies, schools, and corporations.

AVTI的投资论点是什么？

Avitar, Inc. presents a speculative investment opportunity within the medical devices and diagnostics sector. With a negative P/E ratio and a negative profit margin of -72.7%, the company's financial performance raises concerns about its profitability and sustainability. The company's gross margin stands at 26.9%. Growth catalysts include potential expansion of its ORALscreen product line into new markets and increased adoption of its wound care products. However, the company's small market capitalization and OTC listing introduce significant risks related to liquidity and regulatory compliance. The company's high beta of -51.52 suggests high volatility relative to the market. Investors should carefully consider these factors and conduct thorough due diligence before investing.

AVTI在哪个行业运营？

Avitar, Inc. operates within the medical devices and diagnostics industry, a sector characterized by technological innovation and stringent regulatory oversight. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in diagnostic technologies. Competition is intense, with established players and emerging companies vying for market share. Avitar's focus on onsite drug detection and specialized wound care products positions it within niche segments of this broader market. The company's success depends on its ability to innovate, obtain regulatory approvals, and effectively market its products.

Medical - Devices

Healthcare

AVTI有哪些增长机遇？

Expansion of ORALscreen product line: Avitar has the opportunity to expand the market reach of its ORALscreen drug detection systems. The market for drug testing is growing, driven by increasing concerns about workplace safety and substance abuse. By targeting new industries and geographies, Avitar can increase sales and market share. The global drug testing market is projected to reach $8.7 billion by 2027, offering a substantial growth opportunity for Avitar.
Increased adoption of wound care products: Avitar's Hydrasorb and Illizarov dressings address specific needs in wound care management. The market for advanced wound care products is expanding due to the rising incidence of chronic wounds and surgical procedures. By focusing on product innovation and strategic partnerships with medical facilities, Avitar can drive adoption of its wound care solutions. The advanced wound care market is expected to reach $22 billion by 2028.
Development of new diagnostic tests: Avitar can leverage its expertise in diagnostic test development to create new products for detecting various medical conditions. The demand for rapid and accurate diagnostic tests is increasing, driven by the need for early disease detection and personalized medicine. By investing in research and development, Avitar can expand its product portfolio and address unmet needs in the diagnostics market. The global diagnostics market is projected to reach $125 billion by 2025.
Strategic partnerships and acquisitions: Avitar can pursue strategic partnerships and acquisitions to expand its product offerings and market reach. Collaborating with other companies in the medical devices and diagnostics industry can provide access to new technologies, distribution channels, and customer segments. By carefully selecting partners and acquisition targets, Avitar can accelerate its growth and enhance its competitive position. The medical device industry is witnessing increasing consolidation, creating opportunities for strategic alliances.
Geographic expansion: Avitar primarily operates in the United States and Canada. Expanding into new geographic markets, such as Europe and Asia, can significantly increase its revenue potential. These regions have growing healthcare expenditures and increasing demand for advanced medical devices and diagnostics. By establishing a presence in these markets through partnerships or direct investment, Avitar can tap into new sources of growth. The emerging markets in Asia are expected to drive significant growth in the healthcare industry.

Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
Negative P/E ratio suggests the company is currently not profitable.
Profit margin of -72.7% highlights significant challenges in achieving profitability.
Gross margin of 26.9% indicates the company's ability to generate revenue after covering the cost of goods sold.
Beta of -51.52 suggests the stock price moves inversely to the market.

AVTI提供哪些产品和服务？

Designs, develops, manufactures, and markets diagnostic test products.
Offers oral fluid-based onsite assay systems for detecting drugs of abuse (ORALscreen 4 and ORALscreen DRUGOMETER).
Provides medical-grade hydrophilic polyurethane foam disposables, including wound dressings (Hydrasorb).
Develops custom foam products for medical and consumer applications.
Creates specialty wound dressings for the cardiac catheter lab market.
Produces the Illizarov Dressing for dressing external bone fixators in orthopedic procedures.

AVTI如何赚钱？

Develops and manufactures diagnostic test products and medical disposables.
Markets products to employers, diagnostic test distributors, medical supply companies, governmental agencies, schools, and corporations.
Utilizes a direct sales force and strategic partners for distribution.
Generates revenue through the sale of diagnostic tests and medical disposables.

Employers seeking drug testing solutions for workplace safety.
Diagnostic test distributors supplying medical facilities and laboratories.
Medical supply companies providing products to hospitals and clinics.
Governmental agencies requiring drug testing and medical supplies.
Schools and corporations implementing drug testing programs.

Proprietary hydrophilic polyurethane foam technology.
Established relationships with strategic partners and distributors.
Specialized product offerings in niche markets (e.g., Illizarov Dressing).
Brand recognition for ORALscreen drug detection systems.

什么因素可能推动AVTI股价上涨？

Upcoming: Potential FDA approval for new diagnostic tests, expanding the product portfolio.
Ongoing: Expansion of the ORALscreen product line into new geographic markets.
Ongoing: Strategic partnerships with medical facilities to increase adoption of wound care products.

AVTI的主要风险是什么？

Potential: Competition from larger companies in the medical devices and diagnostics industry.
Potential: Regulatory changes affecting drug testing and medical device approvals.
Ongoing: Negative profitability and low market capitalization.
Ongoing: OTC listing introduces liquidity and regulatory risks.
Potential: Product liability claims and recalls.

AVTI的核心优势是什么？

Proprietary technology in hydrophilic polyurethane foam.
Established presence in the drug detection market with ORALscreen.
Specialized wound care products addressing specific medical needs.
Direct sales force and strategic partnerships for distribution.

AVTI的劣势是什么？

Negative profitability and low market capitalization.
Limited financial resources for research and development.
Dependence on a small number of products and markets.
OTC listing introduces liquidity and regulatory risks.

AVTI有哪些机遇？

Expansion of ORALscreen product line into new markets.
Increased adoption of wound care products in hospitals and clinics.
Development of new diagnostic tests for various medical conditions.
Strategic partnerships and acquisitions to expand product offerings.

AVTI面临哪些威胁？

Competition from larger companies in the medical devices and diagnostics industry.
Regulatory changes affecting drug testing and medical device approvals.
Economic downturn impacting healthcare spending.
Product liability claims and recalls.

AVTI的竞争对手是谁？

BioMedomics, Inc. — Focuses on point-of-care diagnostics. — (BMGP)
Cantech Scientific, Inc. — Offers diagnostic and research products. — (CNTTQ)
Fidelity Biosciences Healthcare Fund — Venture capital fund investing in healthcare companies. — (FDBH)
iXensor Co., Ltd. — Develops mobile health and point-of-care testing solutions. — (IXSBF)
Origin Health Corp. — Focuses on healthcare and wellness products. — (ORHB)

Key Metrics

MoonshotScore: 45/100

Company Profile

CEO: Cory H. Gelmon
Headquarters: Canton, US
Employees: 36
Founded: 1994

AI Insight

AI analysis pending for AVTI

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Avitar, Inc. do?

Avitar, Inc. is a holding company that, through its subsidiaries, focuses on designing, developing, manufacturing, and marketing diagnostic test products and proprietary hydrophilic polyurethane foam disposables. Their primary offerings include ORALscreen drug detection systems and Hydrasorb wound dressings, targeting the medical, diagnostic, dental, and consumer sectors. The company distributes its products through a direct sales force, strategic partners, and a network of distributors, serving employers, medical facilities, governmental agencies, and schools.

What do analysts say about AVTI stock?

AI analysis is currently pending for AVTI. Given the company's OTC listing and limited financial information, analyst coverage is likely sparse. Key valuation metrics such as P/E ratio are currently negative, reflecting the company's lack of profitability. Growth considerations include the potential for expansion in the drug testing and wound care markets, but investors should carefully assess the risks associated with investing in a micro-cap OTC stock.

What are the main risks for AVTI?

Avitar, Inc. faces several risks, including intense competition in the medical devices and diagnostics industry, regulatory hurdles related to drug testing and medical device approvals, and the company's current lack of profitability. As an OTC-listed company, AVTI is subject to liquidity constraints and limited regulatory oversight, increasing the risk of price volatility and potential fraud. Investors should also consider the potential for product liability claims and recalls, which could negatively impact the company's financial performance and reputation.